In this Drug Science webinar, Dr Balázs Szigeti explains the current science of microdosing as he presents the results from his self-blinded microdosing research, the largest placebo-controlled microdosing study in the world! Dr Szigeti also explains how participants created their microdoses with a placebo control as part of the revolutionary methodology he developed to reduce …
Summary Full Report Survey Data Does the UK support psilocybin research? Public perceptions of psilocybin-assisted therapy have been revealed in a new YouGov poll, commissioned by Drug Science. This is the first nationally representative poll of UK attitudes towards the medicalisation of psilocybin and support for policy changes (such as rescheduling psilocybin) to make this …
In this Drug Science webinar, expert Neuropsychopharmacologist Professor David Nutt explains how psychedelic drugs such as psilocybin, LSD, DMT, and ayahuasca work in the human brain, and the applications for the treatment of mental health conditions such as depression, anxiety, and addiction. Prof Nutt outlines the history of psychedelic research, starting in the early 20th …
There appears to be a growing disconnection between humans and their natural environments which has been linked to poor mental health and ecological destruction. Research shows that psychedelic usage is associated with enduring increases in nature connectedness. What makes psychedelics such as psilocybin promising agents for enhancing nature connectedness, and what are the potential implications …
What is the role of psychological support in psychedelic treatments? In this webinar, Dr Sara Tai will explain why it is essential that psychedelic drugs such as psilocybin are administered in conjunction with psychotherapy. In such treatments, psychotherapy is primarily delivered at three distinct phases: Preparation for the psychedelic experience Guiding the psychedelic experience Integration …
In this webinar, Dr Meg Spriggs explains the potential of psilocybin to treat anorexia nervosa, and offers valuable insights from the clinical trial investigating this application at the Centre for Psychedelic Research. Eating disorders are a complex mental health issue with few effective pharmaceutical treatments available. Meg provides an introductory background to some of the …
After the release of the first comparison of psilocybin with an SSRI antidepressant, Michelle Baker Jones & Leonie Schneider explain what psilocybin therapy for depression involves. Leonie was a patient of Michelle in psilodep 1, and together they provide insight into psilocybin therapy from the perspective of both therapist and patient. Michelle Baker Jones is …